Swiss pharmaceutical group Helsinn has implemented a new organisational structure and in the process has made some changes to personnel.
Swiss pharmaceutical group Helsinn has implemented a new organisational structure and in the process has made some changes to personnel. Riccardo Braglia has become ceo of the Helsinn Group and will focus on internal and external growth, and new market openings. He also takes charge of the market-direct sales project at Helsinn Therapeutics US, which will be coordinated by Andrea Meoli, who has become chief commercial officer.
Giorgio Calderari, formerly chief operating officer, has been promoted to group general manager, taking responsibility for all corporate functions, including business development, which will be headed by Roberto De Ponti; r&d, assigned to Sergio Cantoreggi, newly appointed chief scientific officer; technical affairs managed by Daniele Bonadeo; commercial, headed by Meoli; and manufacturing run by Paolo Guainazzi and Padraig Somers.
Gabriele Braglia, Helsinn Group founder, retains his role as chairman.
Luigi Caletti has been confirmed as chief financial officer, and Matteo Missaglia, appointed as head of corporate legal affairs, will report directly to Braglia.